Moderna Inc (MRNA)

[axelvento]

2023 Advanced Purchase Agreements

BIG COMPANY,,,,,,,,,


Confirmed APAs, as well as previously deferred product sales, currently represent $4.5-$5.5 billion in anticipated product sales in 2023. The Company expects additional sales in key markets, including the U.S., E.U., Japan, Middle East, Latin America and Asia Pacific in 2023.


From the end of the third quarter of 2021 to the end of the third quarter of 2022, the Company repurchased 24 million shares, reducing the number of common shares outstanding from 405 million to 387 million, more than offsetting 5 million shares of common stock issued in connection with equity compensation over this period.

CMV vaccine (mRNA-1647) pivotal Phase 3 study, known as CMVictory, is ongoing.

$MRNA